NJS

NJS Associates is a specialized contract research organization (CRO) founded in 2011 and based in Bridgewater, New Jersey, providing biostatistics and statistical programming services to the life sciences industry. The company supports drug development programs from Phase I through Phase IV, offering expertise in clinical data management, SAS programming, and statistical methodology for regulatory submissions. NJS has a significant track record in oncology and rare diseases, having supported over 100 clinical trials and contributed to at least ten FDA approvals, including a notable role as the biostatistics and programming designee for Moderna's COVID-19 vaccine trials. By leveraging advanced Bayesian methodologies and proprietary SAS macro systems, NJS empowers biotechnology firms with high-level analytical insights to enhance the quality of efficacy data and optimize clinical trial outcomes.